Keren Holmes, MD
Family Medicine · Nashville, TNNPI 1871614370
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $35,800 of the $57,634 with a category attached, or 62.1%. Lilly USA, LLC accounts for 87.4% of it on its own, with 36 other manufacturers making up the rest. 2025 is the largest year on record at $29,415, more than ten times the $1,442 reported in 2019. Among family medicine clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 569 payments — averaging $101.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$50K
- Novo Nordisk$1K
- Pfizer$993
- AbbVie$943
- AstraZeneca$626
- Amgen$453
- plus $3K from 31 others
What the payments were for
- Consulting fees$8,80015%
- Speaking & faculty fees$35,80062%
- Travel & lodging$2,4904%
- Food & beverage$10,53018%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 138 | $50,362 |
| Novo Nordisk | 84 | $1,296 |
| Pfizer | 55 | $993 |
| AbbVie(2 entities) | 59 | $943 |
| AstraZeneca | 31 | $626 |
| Amgen | 26 | $453 |
| Sanofi-aventis U.S. LLC | 17 | $304 |
| Boehringer Ingelheim | 14 | $248 |
| Abbott | 12 | $229 |
| Johnson & Johnson | 14 | $225 |
| Merck | 15 | $201 |
| Exact Sciences | 11 | $192 |
| Novartis | 10 | $184 |
| GSK | 11 | $161 |
| Amarin Pharma, Inc. | 7 | $126 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $106 |
| Astellas Pharma US Inc | 5 | $89 |
| Theratechnologies Inc. | 6 | $85 |
| Bayer | 4 | $80 |
| Biohaven Pharmaceuticals, Inc. | 4 | $77 |
| Esperion Therapeutics, Inc. | 4 | $73 |
| Upsher-smith Laboratories LLC | 3 | $68 |
| Teva Pharmaceuticals USA, Inc. | 4 | $55 |
| Bausch Health US, LLC | 2 | $45 |
| Gilead | 3 | $44 |
| Idorsia Pharmaceuticals US Inc | 2 | $43 |
| Viiv Healthcare Company | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 3 | $40 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Eisai Inc. | 3 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $35 |
| Nestle Healthcare Nutrition Inc. | 2 | $34 |
| Dexcom, Inc. | 2 | $27 |
| Cequr Corporation | 1 | $21 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Mylan Institutional Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$57,634 in reported general payments places this provider in the 95th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 32 | $34,196 |
| FarxigaDapagliflozin Propanediol | 14 | $12,613 |
| OzempicSemaglutide | 13 | $11,960 |
| Icosapent Ethyl | 14 | $3,513 |
| Valsartan | 47 | $2,082 |
| Atorvastatin Calcium | 122 | $1,844 |
| SynthroidLevothyroxine Sodium | 16 | $1,602 |
| Rosuvastatin Calcium | 81 | $1,508 |
| Omeprazole | 62 | $1,120 |
| Nebivolol Hcl | 12 | $1,082 |
| Levothyroxine Sodium | 113 | $1,043 |
| Losartan Potassium | 87 | $1,038 |
| Metoprolol Succinate | 51 | $985 |
| Oxycodone Hcl | 12 | $901 |
| Gabapentin | 40 | $893 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $50,362 | $34,19632 claims |
| AstraZenecaFarxiga | $626 | $12,61314 claims |
| Novo NordiskOzempic | $1,296 | $11,96013 claims |
| AbbVieSynthroid | $943 | $1,60216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Nashville
- Burton SandersNashville$19K
- Julia GomezNashville$18K
- Christopher HoffmanNashville$17K
- John AdewumiNashville$15K
- Kevin DennisFranklin$354K
- Charolette JacksonBartlett$162K
- Kabir Harricharan SinghNewport$49K
- Khaisha GistAntioch$49K
- Jerry PunchKnoxville$45K
- Christopher HollowayAntioch$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.